RxDoctor Payments Data

Larisa Syrow, MD

Neurology · Brooklyn, NYNPI 1639364037

Payments from drug & device makers

$149,616in general payments, 2019–2025

Across 440 payments — averaging $340.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$37K
  • Biohaven Pharmaceuticals, Inc.$31K
  • Teva Pharmaceuticals USA, Inc.$29K
  • AbbVie$28K
  • Impel Pharmaceuticals Inc.$16K
  • Biohaven Pharmaceutical Holding Company Ltd.$7K
  • plus $2K from 22 others

What the payments were for

  • Consulting fees$17,17211%
  • Speaking & faculty fees$120,65281%
  • Travel & lodging$2,8522%
  • Food & beverage$8,8186%
  • Education$1220%

General payments by program year

19
20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$149,616 in reported general payments places this provider in the 85th percentile of 1,623 neurology providers in New York.

See all neurology providers in New York

Medicare billing

Part B allowed, 2024
$54,144
Medicare patients
276
Services billed
411

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
UbrelvyUbrogepant141$224,773
Nurtec OdtRimegepant Sulfate112$214,196
Emgality PenGalcanezumab-Gnlm102$100,764
QuliptaAtogepant84$91,856
Ajovy AutoinjectorFremanezumab-Vfrm63$68,035
Aimovig AutoinjectorErenumab-Aooe76$67,329
AptiomEslicarbazepine Acetate21$27,996
Sumatriptan Succinate189$26,426
HorizantGabapentin Enacarbil15$16,674
ReyvowLasmiditan Succinate15$12,995
Tetrabenazine13$7,627
Sumatriptan24$6,697
Oxcarbazepine22$3,362
Lacosamide25$2,609
RizatriptanRizatriptan Benzoate103$2,258

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieUbrelvy, Qulipta$27,707$316,628225 claims
Sunovion Pharmaceuticals Inc.Aptiom$39$27,99621 claims
Lilly USA, LLCReyvow, Olanzapine$67$13,28230 claims
Upsher-smith Laboratories LLCTopiramate$14$2,022170 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,623 neurology providers in New York.

Other neurology in Brooklyn

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →